Seres Health Inc., of Cambridge, Mass., said it closed a $10 million series B financing that included existing investors Flagship Ventures and Enso Ventures, along with new investors such as the Mayo Clinic, Alexandria Venture Investments and several private investors. Proceeds will be used to advance its pipeline of Ecobiotic therapeutics, including lead candidate SER-109, which is in testing for recurrent Clostridium difficile. Ecobiotics are designed to target the underlying biology of the human microbiome. The company also entered an exclusive research collaboration with the Mayo Clinic, under which the two will define diseases for which a microbiome-based intervention may be effective and work on discovery and development of key means to treat such conditions.